The Business of Fashion

Novo Nordisk’s “Super Ozempic” Trial Disappoints Again

The drugmaker’s shares dropped after releasing weaker-than-expected trial results for next generation drug CagriSema, which failed to outperform Eli Lilly’s Mounjaro.

Mar 10, 2025 - 17:20
 0
Novo Nordisk’s “Super Ozempic” Trial Disappoints Again
The drugmaker’s shares dropped after releasing weaker-than-expected trial results for next generation drug CagriSema, which failed to outperform Eli Lilly’s Mounjaro.
Read More

Tags:

Previous Article

What the world needs now is more fossil fuels, says Trump’s energy secretary

Next Article

Hudson’s Bay to restructure business in Canada as operations continue

Related Posts

Milan Day Three: Visions of Femininity

Milan Day Three: Visions of Femininity

Feb 28, 2025  0

Trump FTC Chair Pledges to Keep Aggressive Merger Enforcement

Trump FTC Chair Pledges to Keep Aggressive Merger Enfor...

Feb 24, 2025  0

The Race to Own Heatless Curls Heats Up

The Race to Own Heatless Curls Heats Up

Mar 3, 2025  0